Works matching AU Kusakabe, Atsunori

Results: 40
    1

    Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 4, p. 311, doi. 10.1159/000541455
    By:
    • Kato, Daisuke;
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Okayama, Kohei;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Hayashi, Katsumi;
    • Kusakabe, Atsunori;
    • Hasegawa, Izumi;
    • Matoya, Sho;
    • Mizoshita, Tsutomu;
    • Kimura, Yoshihide;
    • Kondo, Hiromu;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    2

    Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study.

    Published in:
    Oncology, 2024, v. 102, n. 8, p. 676, doi. 10.1159/000536367
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Kato, Daisuke;
    • Kusakabe, Atsunori;
    • Koguchi, Hiroki;
    • Hasegawa, Izumi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Tanaka, Yoshito;
    • Kondo, Hiromu;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Kuno, Kayoko;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke
    Publication type:
    Article
    3

    Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.

    Published in:
    JGH Open, 2023, v. 7, n. 6, p. 424, doi. 10.1002/jgh3.12914
    By:
    • Ishido, Shun;
    • Tamaki, Nobuharu;
    • Kurosaki, Masayuki;
    • Mori, Nami;
    • Tsuji, Keiji;
    • Hasebe, Chitomi;
    • Mashiba, Toshie;
    • Ochi, Hironori;
    • Yasui, Yutaka;
    • Akahane, Takehiro;
    • Furuta, Koichiro;
    • Kobashi, Haruhiko;
    • Fujii, Hideki;
    • Ishii, Toru;
    • Marusawa, Hiroyuki;
    • Kondo, Masahiko;
    • Kusakabe, Atsunori;
    • Yoshida, Hideo;
    • Uchida, Yasushi;
    • Tada, Toshifumi
    Publication type:
    Article
    4
    5
    6
    7

    Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 10, p. 2158, doi. 10.1111/jgh.16672
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Kusakabe, Atsunori;
    • Narahara, Satoshi;
    • Tokunaga, Takayuki;
    • Nagaoka, Katsuya;
    • Murakami, Shuko;
    • Inoue, Takako;
    • Kuroyanagi, Keita;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    8
    9
    10
    11
    12

    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

    Published in:
    PLoS ONE, 2018, v. 13, n. 4, p. 1, doi. 10.1371/journal.pone.0194704
    By:
    • Mashiba, Toshie;
    • Joko, Kouji;
    • Kurosaki, Masayuki;
    • Ochi, Hironori;
    • Osaki, Yukio;
    • Kojima, Yuji;
    • Nakata, Ryo;
    • Goto, Tohru;
    • Takehiro, Akahane;
    • Kimura, Hiroyuki;
    • Mitsuda, Akeri;
    • Kawanami, Chiharu;
    • Uchida, Yasushi;
    • Ogawa, Chikara;
    • Kusakabe, Atsunori;
    • Narita, Ryuichi;
    • Ide, Yasushi;
    • Abe, Takehiko;
    • Tsuji, Keiji;
    • Kitamura, Tadashi
    Publication type:
    Article
    13

    Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group

    Published in:
    Journal of Viral Hepatitis, 2022, v. 29, n. 7, p. 551, doi. 10.1111/jvh.13684
    By:
    • Mashiba, Toshie;
    • Joko, Kouji;
    • Kurosaki, Masayuki;
    • Ochi, Hironori;
    • Marusawa, Hiroyuki;
    • Uchida, Yasushi;
    • Fujii, Hideki;
    • Kojima, Yuji;
    • Yoshida, Hideo;
    • Goto, Tohru;
    • Akahane, Takehiro;
    • Kondo, Masahiko;
    • Tsuji, Keiji;
    • Mitsuda, Akeri;
    • Hasebe, Chitomi;
    • Kusakabe, Atsunori;
    • Sohda, Tetsuro;
    • Furuta, Koichiro;
    • Kobashi, Haruhiko;
    • Ogawa, Chikara
    Publication type:
    Article
    14

    Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.

    Published in:
    Investigational New Drugs, 2023, v. 41, n. 2, p. 340, doi. 10.1007/s10637-023-01349-4
    By:
    • Takaki, Shintaro;
    • Kurosaki, Masayuki;
    • Mori, Nami;
    • Tsuji, Keiji;
    • Ochi, Hironori;
    • Marusawa, Hiroyuki;
    • Nakamura, Shinichiro;
    • Tada, Toshifumi;
    • Narita, Ryoichi;
    • Uchida, Yasushi;
    • Akahane, Takehiro;
    • Kondo, Masahiko;
    • Kusakabe, Atsunori;
    • Furuta, Koichiro;
    • Kobashi, Haruhiko;
    • Arai, Hirotaka;
    • Nonogi, Michiko;
    • Tamada, Takashi;
    • Hasebe, Chitomi;
    • Ogawa, Chikara
    Publication type:
    Article
    15

    Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 6, p. 1290, doi. 10.1007/s10637-022-01303-w
    By:
    • Tamaki, Nobuharu;
    • Tada, Toshifumi;
    • Kurosaki, Masayuki;
    • Yasui, Yutaka;
    • Ochi, Hironori;
    • Mashiba, Toshie;
    • Sakamoto, Azusa;
    • Marusawa, Hiroyuki;
    • Narita, Ryoichi;
    • Uchida, Yasushi;
    • Akahane, Takehiro;
    • Kondo, Masahiko;
    • Mori, Nami;
    • Takaki, Shintaro;
    • Tsuji, Keiji;
    • Kobashi, Haruhiko;
    • Kusakabe, Atsunori;
    • Furuta, Koichiro;
    • Arai, Hirotaka;
    • Nonogi, Michiko
    Publication type:
    Article
    16

    Case–control study for the identification of virological factors associated with fulminant hepatitis B.

    Published in:
    Hepatology Research, 2009, v. 39, n. 7, p. 648, doi. 10.1111/j.1872-034X.2009.00519.x
    By:
    • Kusakabe, Atsunori;
    • Tanaka, Yasuhito;
    • Mochida, Satoshi;
    • Nakayama, Nobuaki;
    • Inoue, Kazuaki;
    • Sata, Michio;
    • Isoda, Norio;
    • Kang, Jong-Hon;
    • Sumino, Yasukiyo;
    • Yatsuhashi, Hiroshi;
    • Takikawa, Yasuhiro;
    • Kaneko, Shuichi;
    • Yamada, Gotaro;
    • Karino, Yoshiyasu;
    • Tanaka, Eiji;
    • Kato, Junji;
    • Sakaida, Isao;
    • Izumi, Namiki;
    • Sugauchi, Fuminaka;
    • Nojiri, Shunsuke
    Publication type:
    Article
    17

    A case–control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C

    Published in:
    Hepatology Research, 2006, v. 35, n. 2, p. 127, doi. 10.1016/j.hepres.2006.03.005
    By:
    • Orito, Etsuro;
    • Fujiwara, Kei;
    • Tanaka, Yasuhito;
    • Yuen, Man-Fung;
    • Lai, Ching-Lung;
    • Kato, Takanobu;
    • Sugauchi, Fuminaka;
    • Kusakabe, Atsunori;
    • Sata, Michio;
    • Okanoue, Takeshi;
    • Niitsuma, Hirofumi;
    • Sakugawa, Hiroshi;
    • Hasegawa, Izumi;
    • Mizokami, Masashi
    Publication type:
    Article
    18

    Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 1, p. 1, doi. 10.1002/cam4.6876
    By:
    • Takanori Suzuki;
    • Kentaro Matsuura;
    • Yuta Suzuki;
    • Fumihiro Okumura;
    • Yoshihito Nagura;
    • Satoshi Sobue;
    • Sho Matoya;
    • Tomokatsu Miyaki;
    • Yoshihide Kimura;
    • Atsunori Kusakabe;
    • Satoshi Narahara;
    • Takayuki Tokunaga;
    • Katsuya Nagaoka;
    • Keita Kuroyanagi;
    • Hayato Kawamura;
    • Kayoko Kuno;
    • Kei Fujiwara;
    • Shunsuke Nojiri;
    • Hiromi Kataoka;
    • Yasuhito Tanaka
    Publication type:
    Article
    19

    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.

    Published in:
    2019
    By:
    • Iio, Etsuko;
    • Matsuura, Kentaro;
    • Shimada, Noritomo;
    • Atsukawa, Masanori;
    • Itokawa, Norio;
    • Abe, Hiroshi;
    • Kato, Keizo;
    • Takaguchi, Koichi;
    • Senoh, Tomonori;
    • Eguchi, Yuichiro;
    • Nomura, Hideyuki;
    • Yoshizawa, Kai;
    • Kang, Jong-Hon;
    • Matsui, Takeshi;
    • Hirashima, Noboru;
    • Kusakabe, Atsunori;
    • Miyaki, Tomokatsu;
    • Fujiwara, Kei;
    • Matsunami, Kayoko;
    • Tsutsumi, Susumu
    Publication type:
    journal article
    20

    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.

    Published in:
    2018
    By:
    • Tsuji, Keiji;
    • Kurosaki, Masayuki;
    • Itakura, Jun;
    • Mori, Nami;
    • Takaki, Shintaro;
    • Hasebe, Chitomi;
    • Akahane, Takehiro;
    • Joko, Kouji;
    • Yagisawa, Hitoshi;
    • Takezawa, Jirou;
    • Nakata, Ryou;
    • Kusakabe, Atsunori;
    • Kojima, Yuji;
    • Kimura, Hiroyuki;
    • Tamada, Takashi;
    • Kobashi, Haruhiko;
    • Mitsuda, Akeri;
    • Kondou, Masahiko;
    • Ogawa, Chikara;
    • Uchida, Yasushi
    Publication type:
    journal article
    21

    Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.

    Published in:
    2017
    By:
    • Iio, Etsuko;
    • Shimada, Noritomo;
    • Abe, Hiroshi;
    • Atsukawa, Masanori;
    • Yoshizawa, Kai;
    • Takaguchi, Koichi;
    • Eguchi, Yuichiro;
    • Nomura, Hideyuki;
    • Kuramitsu, Tomoyuki;
    • Kang, Jong-Hon;
    • Matsui, Takeshi;
    • Hirashima, Noboru;
    • Tsubota, Akihito;
    • Kusakabe, Atsunori;
    • Hasegawa, Izumi;
    • Miyaki, Tomokatsu;
    • Shinkai, Noboru;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Tanaka, Yasuhito
    Publication type:
    journal article
    22
    23
    24

    Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.

    Published in:
    Journal of Medical Virology, 2023, v. 95, n. 1, p. 1, doi. 10.1002/jmv.28210
    By:
    • Kaneko, Shun;
    • Kurosaki, Masayuki;
    • Mashiba, Toshie;
    • Marusawa, Hiroyuki;
    • Kondo, Masahiko;
    • Kojima, Yuji;
    • Uchida, Yasushi;
    • Fujii, Hideki;
    • Akahane, Takehiro;
    • Yagisawa, Hitoshi;
    • Kusakabe, Atsunori;
    • Kobashi, Haruhiko;
    • Abe, Takehiko;
    • Yoshida, Hideo;
    • Ogawa, Chikara;
    • Furuta, Koichiro;
    • Tamaki, Nobuharu;
    • Tsuji, Keiji;
    • Matsushita, Tomomichi;
    • Izumi, Namiki
    Publication type:
    Article
    25

    Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.

    Published in:
    Journal of Medical Virology, 2021, v. 93, n. 11, p. 6247, doi. 10.1002/jmv.27157
    By:
    • Tada, Toshifumi;
    • Kurosaki, Masayuki;
    • Nakamura, Shinichiro;
    • Hasebe, Chitomi;
    • Kojima, Yuji;
    • Furuta, Koichiro;
    • Kobashi, Haruhiko;
    • Kimura, Hiroyuki;
    • Ogawa, Chikara;
    • Yagisawa, Hitoshi;
    • Uchida, Yasushi;
    • Joko, Kouji;
    • Akahane, Takehiro;
    • Arai, Hirotaka;
    • Marusawa, Hiroyuki;
    • Narita, Ryoichi;
    • Ide, Yasushi;
    • Sato, Takashi;
    • Kusakabe, Atsunori;
    • Tsuji, Keiji
    Publication type:
    Article
    26

    The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Hepatology Research, 2023, v. 53, n. 6, p. 511, doi. 10.1111/hepr.13886
    By:
    • Matoya, Sho;
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Kuroyanagi, Keita;
    • Kusakabe, Atsunori;
    • Koguchi, Hiroki;
    • Hasegawa, Izumi;
    • Miyaki, Tomokatsu;
    • Tanaka, Yoshito;
    • Kondo, Hiromu;
    • Kimura, Yoshihide;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Kuno, Kayoko;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke
    Publication type:
    Article
    27

    Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.

    Published in:
    Hepatology Research, 2023, v. 53, n. 4, p. 289, doi. 10.1111/hepr.13864
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Urakabe, Kenji;
    • Okumura, Fumihiro;
    • Kawamura, Hayato;
    • Sobue, Satoshi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Kato, Daisuke;
    • Kusakabe, Atsunori;
    • Tanaka, Yoshito;
    • Ozasa, Atsushi;
    • Nagura, Yoshihito;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Hagiwara, Shinya;
    • Kusumoto, Shigeru;
    • Inoue, Takako;
    • Tanaka, Yasuhito
    Publication type:
    Article
    28

    Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma.

    Published in:
    Hepatology Research, 2023, v. 53, n. 1, p. 61, doi. 10.1111/hepr.13836
    By:
    • Ochi, Hironori;
    • Kurosaki, Masayuki;
    • Joko, Kouji;
    • Mashiba, Toshie;
    • Tamaki, Nobuharu;
    • Tsuchiya, Kaoru;
    • Marusawa, Hiroyuki;
    • Tada, Toshifumi;
    • Nakamura, Shinichiro;
    • Narita, Ryoichi;
    • Uchida, Yasushi;
    • Akahane, Takehiro;
    • Kondo, Masahiko;
    • Mori, Nami;
    • Takaki, Shintaro;
    • Tsuji, Keiji;
    • Kusakabe, Atsunori;
    • Furuta, Koichiro;
    • Kobashi, Haruhiko;
    • Arai, Hirotaka
    Publication type:
    Article
    29
    30

    Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.

    Published in:
    Hepatology Research, 2019, v. 49, n. 10, p. 1114, doi. 10.1111/hepr.13362
    By:
    • Mashiba, Toshie;
    • Joko, Kouji;
    • Kurosaki, Masayuki;
    • Ochi, Hironori;
    • Hasebe, Chitomi;
    • Akahane, Takehiro;
    • Sohda, Tetsuro;
    • Tsuji, Keiji;
    • Mitsuda, Akeri;
    • Kimura, Hiroyuki;
    • Narita, Ryoichi;
    • Ogawa, Chikara;
    • Furuta, Koichiro;
    • Shigeno, Masaya;
    • Okushin, Hiroaki;
    • Ito, Hiroshi;
    • Kusakabe, Atsunori;
    • Satou, Takashi;
    • Kawanami, Chiharu;
    • Nakata, Ryo
    Publication type:
    Article
    31

    Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.

    Published in:
    Hepatology Research, 2019, v. 49, n. 3, p. 264, doi. 10.1111/hepr.13246
    By:
    • Akahane, Takehiro;
    • Kurosaki, Masayuki;
    • Itakura, Jun;
    • Tsuji, Keiji;
    • Joko, Kouji;
    • Kimura, Hiroyuki;
    • Nasu, Akihiro;
    • Ogawa, Chikara;
    • Kojima, Yuji;
    • Hasebe, Chitomi;
    • Wada, Shuichi;
    • Uchida, Yasushi;
    • Sohda, Tetsuro;
    • Suzuki, Hideyuki;
    • Yoshida, Hideo;
    • Kusakabe, Atsunori;
    • Tamada, Takashi;
    • Kobashi, Haruhiko;
    • Mitsuda, Akeri;
    • Kondo, Masahiko
    Publication type:
    Article
    32

    Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis.

    Published in:
    Hepatology Research, 2018, v. 48, n. 9, p. 746, doi. 10.1111/hepr.13070
    By:
    • Fujii, Hideki;
    • Kimura, Hiroyuki;
    • Kurosaki, Masayuki;
    • Hasebe, Chitomi;
    • Akahane, Takehiro;
    • Yagisawa, Hitoshi;
    • Kato, Keizo;
    • Yoshida, Hideo;
    • Itakura, Jun;
    • Sakita, Shinya;
    • Satou, Takashi;
    • Okada, Kazuhiko;
    • Kusakabe, Atsunori;
    • Kojima, Yuji;
    • Kondo, Masahiko;
    • Morita, Atsuhiro;
    • Nasu, Akihiro;
    • Tamada, Takashi;
    • Okushin, Hiroaki;
    • Kobashi, Haruhiko
    Publication type:
    Article
    33

    Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.

    Published in:
    Hepatology Research, 2017, v. 47, n. 12, p. 1308, doi. 10.1111/hepr.12898
    By:
    • Iio, Etsuko;
    • Shimada, Noritomo;
    • Takaguchi, Koichi;
    • Senoh, Tomonori;
    • Eguchi, Yuichiro;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Abe, Hiroshi;
    • Kato, Keizo;
    • Kusakabe, Atsunori;
    • Miyaki, Tomokatsu;
    • Matsuura, Kentaro;
    • Matsunami, Kayoko;
    • Shinkai, Noboru;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Tanaka, Yasuhito
    Publication type:
    Article
    34
    35

    Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C.

    Published in:
    Hepatology Research, 2014, v. 44, n. 12, p. 1208, doi. 10.1111/hepr.12294
    By:
    • Matsuura, Kentaro;
    • Watanabe, Tsunamasa;
    • Iijima, Sayuki;
    • Murakami, Shuko;
    • Fujiwara, Kei;
    • Orito, Etsuro;
    • Iio, Etsuko;
    • Endo, Mio;
    • Kusakabe, Atsunori;
    • Shinkai, Noboru;
    • Miyaki, Tomokatsu;
    • Nojiri, Shunsuke;
    • Joh, Takashi;
    • Tanaka, Yasuhito
    Publication type:
    Article
    36

    Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial.

    Published in:
    Hepatology Research, 2011, v. 41, n. 6, p. 505, doi. 10.1111/j.1872-034X.2011.00807.x
    By:
    • Matsuura, Kentaro;
    • Tanaka, Yasuhito;
    • Kusakabe, Atsunori;
    • Hige, Shuhei;
    • Inoue, Jun;
    • Komatsu, Masashi;
    • Kuramitsu, Tomoyuki;
    • Hirano, Katsuharu;
    • Ohno, Tomoyoshi;
    • Hasegawa, Izumi;
    • Kobashi, Haruhiko;
    • Hino, Keisuke;
    • Hiasa, Yoichi;
    • Nomura, Hideyuki;
    • Sugauchi, Fuminaka;
    • Nojiri, Shunsuke;
    • Joh, Takashi;
    • Mizokami, Masashi
    Publication type:
    Article
    37
    38

    The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.

    Published in:
    Cancers, 2021, v. 13, n. 11, p. 2608, doi. 10.3390/cancers13112608
    By:
    • Tsuchiya, Kaoru;
    • Kurosaki, Masayuki;
    • Sakamoto, Azusa;
    • Marusawa, Hiroyuki;
    • Kojima, Yuji;
    • Hasebe, Chitomi;
    • Arai, Hirotaka;
    • Joko, Kouji;
    • Kondo, Masahiko;
    • Tsuji, Keiji;
    • Sohda, Tetsuro;
    • Kimura, Hiroyuki;
    • Ogawa, Chikara;
    • Uchida, Yasushi;
    • Wada, Shuichi;
    • Kobashi, Haruhiko;
    • Furuta, Koichiro;
    • Shigeno, Masaya;
    • Kusakabe, Atsunori;
    • Akahane, Takehiro
    Publication type:
    Article
    39

    Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.

    Published in:
    Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-69522-w
    By:
    • Kaneko, Shun;
    • Kurosaki, Masayuki;
    • Joko, Kouji;
    • Marusawa, Hiroyuki;
    • Kondo, Masahiko;
    • Kojima, Yuji;
    • Uchida, Yasushi;
    • Kimura, Hiroyuki;
    • Tsuji, Keiji;
    • Yagisawa, Hitoshi;
    • Kusakabe, Atsunori;
    • Kobashi, Haruhiko;
    • Akahane, Takehiro;
    • Tamaki, Nobuharu;
    • Kirino, Sakura;
    • Abe, Takehiko;
    • Yoshida, Hideo;
    • Matsushita, Tomomichi;
    • Hasebe, Chitomi;
    • Izumi, Namiki
    Publication type:
    Article
    40